V-Ensure Pharma Technologies, a contract medication manufacturing company, announced on Tuesday that it had raised Rs 130 crore ($17.5 million) in capital from Investcorp and Tanas Capital, an Asia-based private investment group.
The new funding will be used to seek expansion prospects in North America, Europe, and other global markets for product development and launch.
V-Ensure is a developer of specialty pharmaceutical formulations focused on complicated generics for regulated markets, founded in 2010 by Satyanarayana Vemula. Its key competency is the production of complicated compounds for regulated markets while avoiding patent infringement.
Satyanarayana Vemula, CEO of V-Ensure, said, “We are delighted to partner with Investcorp as we expand our business from a contract research organisation (CRO) to a fully integrated specialty pharmaceutical company. We will continue to deliver patient centric solutions through our proprietary technology and competence in developing complex generics for regulated markets.”